

Validation of multiparametric panels for bovine mesenchymal stromal cell phenotyping

Emma Heyman¹ | M. Meeremans¹ | M. Van Poucke² | L. Peelman² |
 B. Devriendt³ | Catharina De Schauwer¹

¹Veterinary Stem Cell Research Unit, Department of Translational Physiology, Infectiology and Public Health, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium

²Laboratory of Animal Genetics, Department of Veterinary and Biosciences, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium

³Laboratory of Immunology, Department of Translational Physiology, Infectiology and Public Health, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium

Correspondence

Catharina De Schauwer, Veterinary Stem Cell Research Unit, Department of Translational Physiology, Infectiology and Public Health, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
 Email: catharina.deschauwer@ugent.be

Funding information

CUSTOMEAT, Grant/Award Number: S002821N

Abstract

Bovine mesenchymal stromal cells (MSCs) display important features that render them valuable for cell therapy and tissue engineering strategies, such as self-renewal, multi-lineage differentiation, as well as immunomodulatory properties. These cells are also promising candidates to produce cultured meat. For all these applications, it is imperative to unequivocally identify this cell population. The isolation and in vitro tri-lineage differentiation of bovine MSCs is already described, but data on their immunophenotypic characterization is not yet complete. The currently limited availability of monoclonal antibodies (mAbs) specific for bovine MSC markers strongly hampers this research. Following the minimal criteria defined for human MSCs, bovine MSCs should express CD73, CD90, and CD105 and lack expression of CD14 or CD11b, CD34, CD45, CD79 α , or CD19, and MHC-II. Additional surface proteins which have been reported to be expressed include CD29, CD44, and CD106. In this study, we aimed to immunophenotype bovine adipose tissue (AT)-derived MSCs using multi-color flow cytometry. To this end, 13 commercial Abs were screened for recognizing bovine epitopes using the appropriate positive controls. Using flow cytometry and immunofluorescence microscopy, cross-reactivity was confirmed for CD34, CD73, CD79 α , and CD90. Unfortunately, none of the evaluated CD105 and CD106 Abs cross-reacted with bovine cells. Subsequently, AT-derived bovine MSCs were characterized using multi-color flow cytometry based on their expression of nine markers. Bovine MSCs clearly expressed CD29 and CD44, and lacked expression of CD14, CD45, CD73, CD79 α , and MHCII, while a variable expression was observed for CD34 and CD90. In addition, the mRNA transcription level of different markers was analyzed using reverse transcription quantitative polymerase chain reaction. Using these panels, bovine MSCs can be properly immunophenotyped which allows a better characterization of this heterogenous cell population.

KEYWORDS

cattle, cross-reactivity, heterogeneity, MSC characterization, multi-color flow cytometry

1 | INTRODUCTION

Healthy and sustainable food provision for a continuously growing human population is one of the major challenges for the next decades. Within the context of alternative food production methods, cultured meat is a promising avenue for increasing the total supply of high-quality protein and, at the same time, responding to a societal demand for reduced animal slaughtering [1–3]. Traditionally, myosatellite cells are used to produce cultured meat as these skeletal muscle stem cells serve *in vivo* as a robust cell source for skeletal muscle repair [4]. Their proliferation and differentiation potential *in vitro*, however, is limited.

Mesenchymal stromal cells (MSCs) are considered as a promising alternative cell source due to their abundance, their role during muscle development and their ability to differentiate into myocytes, adipocytes, fibroblasts, neuronal and endothelial cells [5–8]. Indeed, MSCs are easily isolated from a variety of sources, such as bone marrow, adipose tissue, and neonatal tissues [9, 10]. Human MSCs are commonly characterized following the guidelines of the International Society for Cellular Therapy (ISCT) [11, 12]: they must be [1] plastic adherent under standard culture conditions; [2] be capable of differentiating toward the osteogenic, adipogenic and chondrogenic lineage; and [3] express surface markers such as CD73, CD90, and CD105 but lack expression of hematopoietic or endothelial markers such as CD11b or CD14, CD34, CD45, CD79 α , or CD19 and MHC class II. However, this definition by cell surface marker expression is constantly evolving. For example, the ISCT has recently stated that CD34 negativity is not as definitive [12], as subpopulations of human adipose tissue-derived MSCs have been shown to express CD34 [13, 14].

The isolation, *in vitro* differentiation and immunophenotype of bovine MSCs has already been reported (Table 1). As shown in Table 1, it is clear that bovine MSCs represent a heterogeneous cell population with differences originating from donor age, tissue of origin, genetic background, passage, and culture conditions [10, 51, 52]. For example, Kato et al. showed that bone marrow (BM)-derived bovine MSCs lacked CD90 expression, while other researchers showed a variable expression of CD90 (Table 1) [53]. Like human MSCs, Rossi et al. confirmed a moderate CD34 expression in amniotic fluid-derived bovine MSCs, while others showed only a low expression (Table 1) [54]. Such heterogeneity may reflect differences in proliferation and differentiation potential, for example, predisposition for dedicated lineages, which is important to identify when considering bovine MSCs as a cell source to produce cultured meat [51, 55].

The expression of MSC markers is often analyzed on the mRNA level using gel electrophoresis or reverse transcription quantitative polymerase chain reaction (RT-qPCR) and/or protein level using single-color flow cytometry. A multi-color flow cytometry protocol enables to simultaneously evaluate the expression of different markers and as such to identify MSC heterogeneity [56, 57]. However, there are currently no specific criteria to immunophenotype bovine MSCs, partly due to the limited availability of bovine-specific monoclonal antibodies (mAbs) or validated cross-reactive mAbs [9], as illustrated by the study of Naraoka et al. Indeed, half of the tested

246 Abs showed cross-reactivity toward bovine epitopes, but 5%–10% was the highest percentage of cross-reactivity reported (for 97 Abs) while only 1%–5% cross-reactivity was reported for 17 Abs [58].

In this study, 13 commercially available Abs were first evaluated for their cross-reactivity using bovine leukocytes (LEU) or bovine umbilical cord endothelial cells (UVECs) as appropriate positive controls. For all evaluated antibodies, flow cytometric results were confirmed using immunofluorescent microscopy. Subsequently, bovine AT-derived MSCs were characterized by tri-lineage differentiation and multi-color flow cytometry using two selected panels consisting of nine Abs in total. Additionally, marker expression was analyzed on the mRNA level by RT-qPCR.

2 | MATERIALS AND METHODS

2.1 | Isolation methods

Bovine umbilical cord veins and blood waste products were obtained from one routine health screening and two adult cows during caesarean section, provided by the Department of Internal Medicine, Reproduction and Population of the Faculty of Veterinary Medicine. Bovine MSCs were isolated from subcutaneous adipose tissue (AT) from seven healthy calves, as part of an external research project, approved by the institutional ethical committee of the Flanders Research Institute for Agriculture, Fisheries and Food (EC 2018/313).

After collection of approximately 5 mL venous blood using EDTA-coated tubes, red blood cells were lysed with a NH₄Cl lysing solution to isolate bovine LEUs. Briefly, upon incubating for 5 min at room temperature (RT), cells were centrifuged for 5 min at 300g at RT. The cell pellet was washed in phosphate buffered saline (PBS) without Ca²⁺/Mg²⁺ (Gibco), centrifuged for 5 min at 300g and finally resuspended in 1 mL low glucose Dulbecco's Modified Eagle Medium (DMEM-LG, Invitrogen) containing 1% fetal bovine serum (FBS, Sigma) [59].

To isolate primary bovine UVECs, tissue was digested using 1 mg/mL collagenase IA (Sigma) and 1.2 mg/mL dispase II (Sigma) for 30 min in a humidified incubator at 38.5°C and 5% CO₂, as previously described [60]. The enzymatic reaction was blocked by flushing the vein with prewarmed PBS + 10% FBS. The solution was then centrifuged for 5 min at 250g at 4°C, resuspended in PBS + 10% FBS and filtered over a 70 μ m cell strainer. The cell suspension was centrifuged for 5 min at 250g at 4°C and the pellet was resuspended in EGM-2 endothelial growth medium (Lonza). The medium was refreshed twice weekly until 70–80% confluency was reached. Cells were passaged until passage 3 prior to use as positive control cells for Ab screening.

Bovine MSCs were isolated from subcutaneous AT ($n = 7$) using an enzymatic digestion method containing 1 mg/mL liberase (Sigma), as previously described [61]. The isolated cells were seeded in culture medium consisting of DMEM-LG, 30% FBS, 10⁻¹¹ M dexamethasone (Sigma), 1% antibiotic-antimycotic solution (Sigma) and 1% L-glutamine (Invitrogen) in a 25 cm² culture flask and cultured at 38.5°C in a humidified atmosphere containing 5% CO₂. After 24 h, non-

TABLE 1 Overview of immunophenotypic profile on mRNA and protein level of bovine mesenchymal stromal cells.

Cellular marker	Expression on	
	mRNA level	Protein level
CD13	+ [15]	+ [16]
CD29	+ [15, 17–31]	+ [15, 17, 19, 21, 24, 26–28, 30–35]
CD44	+ [15, 18–21, 23–27, 29–31, 36]	+ [15, 16, 19, 21, 24–27, 30, 31, 34, 37–39] – [17, 28, 40]
CD49d	ND	+ [16]
CD71	ND	+ [19]
CD73	+ [15, 17–21, 23–28, 30, 31, 41–44]	+ [17, 25, 27, 28, 33, 35, 40, 45–50]
CD90	+ [15, 17, 22–25, 28, 30, 31, 41, 43]	+ [16, 17, 28, 35, 40, 45–50] ± [15]
CD105	+ [15, 17, 22, 23, 28, 29, 41, 43] – [18]	+ [16, 17, 28, 29, 32, 35, 40, 45–47, 49, 50] – ND
CD106	+ [24, 25] – [15, 30]	ND
CD166	+ [15, 19, 20, 24–26, 29, 31] – [30]	+ [29]
MHCI	+ [15, 18, 29]	+ [15]
CD11b	+ [42] – [15]	– [15]
CD14	– [15, 18, 29]	– ND
CD31	– [15]	– ND
CD34	+ [42] – [15, 18–21, 23–27, 29–31, 41, 43]	± [29, 33, 34, 40, 48] – [16, 17, 19, 21, 24, 27, 28, 32, 35, 38, 39, 47, 50]
CD45	+ [41–43] – [15, 19–21, 23–26, 31, 41]	± [33, 48] – [15, 17, 28, 32, 35, 40, 45, 47, 50]
CD79 α	ND	– [40, 47, 50]
CD117	– [15]	– ND
MHCII	– [15, 18, 24, 26, 29, 31]	± [29] – [15, 34, 38, 39]

Note: At the mRNA level, + is defined as presence and – is defined as absence of mRNA (as determined by PCR agarose gel images and/or RT-qPCR). At the protein level, + is defined as presence (> 10%) and – is defined as absence of protein (<2%), ± is defined as relative marker expression between 2% and 10% (as determined by immunofluorescence and western blot images). Percentages are linked to relative marker expression, at the protein level, analyzed using quantitative methods such as flow cytometry.

Abbreviation: ND, not done.

adherent cells were removed by replacing the culture medium. Subsequently, culture medium was replaced twice weekly and cells were passaged as soon as 70%–80% confluency was observed using 2.5 mg/mL trypsin (Sigma)-0.2 mg/mL EDTA (Sigma) in expansion medium (identical to the culture medium without dexamethasone). Cells were passaged until passage 4 prior to use for multi-color flow cytometry.

2.2 | Tri-lineage differentiation of bovine AT-MSCs

To confirm their MSC identity, undifferentiated bovine MSCs of the 3rd passage were induced toward the adipogenic, chondrogenic, and

osteogenic lineage, respectively, as previously described [61]. Non-induced MSCs cultured in expansion medium were used as appropriate negative controls. Adipogenic differentiation was assessed using Oil Red O histological staining with a Mayer's modified hematoxylin (Abcam) counterstaining after cycles of 72 h culturing in adipogenic induction medium (DMEM-LG supplemented with 1 μ M dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine (Sigma), 10 μ g/mL rh-insuline (Sigma), 0.2 mM indomethacin (Sigma), 15% rabbit serum (Sigma), 50 μ g/mL gentamycin (Gibco) and 1% antibiotic-antimycotic solution) and 24 h of culturing in adipogenic maintenance medium (identical to the adipogenic induction medium except for the omission of dexamethasone, indomethacin and 3-isobutyl-1-methylxanthine). Chondrogenic differentiation was evaluated after 21 days of culture

in chondrogenic medium (based on the basal differentiation medium (Lonza), supplemented with 10 ng/mL Transforming Growth Factor- β 3 (Lonza) by Alcian blue (Sigma) histological staining, with 0.1% Nuclear Fast Red (Sigma) counterstaining. Osteogenic differentiation was evaluated after 21 days of culture in osteogenic medium (DMEM-LG supplemented with 10% FBS, 0.05 mM L-ascorbic acid-2-phosphate (Sigma), 100 nM dexamethasone, 10 mM β -glycerophosphate (Sigma), 50 μ g/mL gentamycin and 1% antibiotic-antimycotic solution) using the Alizarin Red S histological staining (Sigma), according to the manufacturer's instructions [59].

2.3 | Single-color flow cytometry

An overview of the primary monoclonal and polyclonal Abs evaluated in this study is given in Table 2. Secondary antibodies included fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse immunoglobulin (IgG) (BioRad), AlexaFluor488 (AF488)-conjugated goat anti-rabbit IgG (Invitrogen), allophycocyanin-cyanine 7 (APC-Cy7)-conjugated goat anti-rabbit IgG (AAT Bioquest), R-phycoerythrin-cyanine 5 (PE-Cy5)-conjugated goat anti-rabbit IgG (ThermoFisher). Additionally, a secondary streptavidin peridinin chlorophyll protein-cyanine5.5 (PerCP-Cy5.5) label (Invitrogen) was used. The isotype controls in this study included mouse IgG₁-APC, IgG₁-FITC and IgG₁-PE-Cy7 (BioLegend).

To screen for Ab reactivity, 500,000 positive control cells (either LEU or UVECs, Table 2) were centrifuged in staining buffer (DMEM +1% FBS) for 5 min at 400g at 4°C and incubated for 30 min at 4°C

in the dark with each of the primary Abs (Table 2). After two washing steps for 5 min at 400 g at 4°C, a FITC-conjugated goat anti-mouse secondary Ab or an AF488-conjugated goat anti-rabbit Ab was added to the cells for 20 min at 4°C in the dark. After one washing step, cell pellets were resuspended in 100 μ L PBS with the viability dye Sytox Blue (0.001 mM; ThermoFisher), following the manufacturer's guidelines. For intracellular antigen detection (CD79 α), cells were fixed and permeabilized using BD Cytofix/Cytoperm™ (BD Biosciences) for 20 min at 4°C prior to primary Ab incubation. At least 10,000 viable single cells were analyzed using a CytoFLEX V2-B4-R3 flow cytometer (Beckman Coulter) equipped with a 405 nm, a 488 nm and a 638 nm laser, and data was subsequently analyzed in the CytExpert software. All data were corrected for autofluorescence as well as for unspecific binding using either secondary Abs alone or isotype-matched negative controls.

2.4 | Immunofluorescence microscopy

Binding of the Abs to the bovine positive control cells was confirmed by immunofluorescence microscopy, as routinely performed [62]. Briefly, cells (either LEU or UVECs) were stained as described for the single-color flow cytometry, and subsequently fixed using 4% paraformaldehyde (PFA) for 20 min at 4°C in the dark. After centrifugation, cells were incubated with 0.01 mg/mL Hoechst33258 (Sigma) to visualize the nuclei, for 20 min at 4°C in the dark. Following centrifugation and a washing step, the stained cells were imaged with a magnification of 63x using fluorescence microscopy (Leica DMi8).

TABLE 2 Overview of the primary antibodies evaluated in this study.

Host	Target species	Antibodies	Isotype	Clone	Company, product number	Positive controls	Cross-reactivity
Ra	Hu, Mo, Rt, Pi	CD34	IgG	Polyclonal	Bioss Antibodies, bs-8996R	UVEC	+
Mo	Hu	CD73-PC7	IgG ₁	AD2	BioLegend, 344,009	LEU	–
Mo	Hu	CD73	IgG _{2b}	45M4F9	Novus Biologicals, NBP2-25237SS	LEU	–
Ra	Hu, Mo, Rt, Sh, Ca	CD73	IgG	Polyclonal	Bioss Antibodies, bs-4834R	LEU	+
Mo	Hu	CD79 α	IgG ₁	HM57	BioRad, MCA2538GA	LEU	+
Mo	Hu	CD90-APC	IgG ₁	5E10	BioLegend, 328133	LEU	–
Mo	Hu	CD90	IgG ₁	AF-9	Novus Biologicals, NBP2-45230	LEU	–
Ra	Hu, Mo, Rt, Ca, Sh, others	CD90	IgG	Polyclonal	Bioss Antibodies, bs-0778R	LEU	+
Mo	Hu	CD105	IgG ₁	SN6h	Invitrogen, MA5-11854	UVEC	–
Rt	Mo, Rt, Hu	CD105	IgG _{2a}	2Q1707	Santa Cruz Biotechnology, sc-71042	UVEC	–
Mo	Hu	CD105-PC7	IgG ₁	SN6	ThermoFisher, 25-1057-42	UVEC	–
Ra	Hu, Mo, Rt	CD105	IgG	Polyclonal	Bioss Antibodies, bs-057R	UVEC	–
Mo	Hu	CD106-FITC	IgG ₁	1.G11B1	BioRad, MCA907F	UVEC	–

Note: Each antibody was tested using the appropriate bovine positive control cells.

Abbreviations: APC, allophycocyanin; Ca, canine; FITC, fluorescein isothiocyanate; Hu, human; LEU, leukocytes; Mo, mouse; PC7, PE-Cyanine7; Pi, pig; Ra, rabbit; Rt, rat; Sh, sheep; UVEC, umbilical cord vein endothelial cells.

2.5 | Multi-color flow cytometry

For multi-color flow cytometry, bovine MSCs of 7 donors were incubated with two panels of both bovine-specific (CD14, CD44, CD45 and MHC-II) and cross-reacting Abs (CD29, CD34, CD73, CD79 α and CD90), as described in Table 3.

Approximately 500,000 cells per tube were centrifuged for 5 min at 400g at 4°C in staining buffer. For panel 1, cells were first incubated for 30 min at 4°C in the dark with a CD73-specific Ab. After blocking and washing with the staining buffer for 5 min at 400g at 4°C, cells were incubated with the appropriate secondary Ab for 20 min at 4°C in the dark. The cells were washed and subsequently blocked for 15 min using 10% rabbit serum in PBS, to block free binding spots of the indirectly labeled primary rabbit CD73-specific Ab.

Next, cells were incubated for 30 min at 4°C in the dark with a biotinylated CD90-specific Ab. After washing with the staining buffer, cells were incubated with a secondary Streptavidin PerCP-Cy5.5 label, together with the directly labeled primary mAbs (CD29-APC, CD45-FITC and MHCII-(R)PE) for 20 min at 4°C in the dark. After a washing step, cell pellets were finally resuspended in 100 μ L PBS with 0.001 mM Sytox Blue.

In panel 2, cells were first stained with a fixable live/dead violet stain (ThermoFisher) for 30 min at 4°C in the dark. After one washing step with PBS, cells were incubated for 30 min at 4°C in the dark with the CD34-specific Ab. After blocking and washing with the staining buffer, cells were incubated with an appropriate secondary Ab together with the directly labeled primary mAbs (CD14-(R)PE and CD44-FITC) for 20 min at 4°C in the dark. Subsequently, cells were fixed and permeabilized using BD Cytofix/Cytoperm™ for 20 min at 4°C. After blocking and washing with 1X Perm/Wash washing buffer, cells were incubated with the CD79 α -AF700 Ab for 20 min at 4°C in the dark. After a washing step, cell pellets were finally resuspended in 100 μ L PBS.

For all panels, at least 10,000 cells were analyzed using a CytoFLEX and CytExpert software. All data were corrected for autofluorescence, compensated and compared to specific fluorescence minus one (FMO) controls. Compensation for spectral overlap between fluorophores was performed using an automatic calibration technique and subsequently evaluated individually with a compensation matrix.

2.6 | RT-qPCR

In order to investigate if the protein levels of the different markers, as analyzed in panel 1 and 2 via multi-color flow cytometry, are reflected in their mRNA levels, RT-qPCR was performed. Approximately 500,000 cells were trypsinized, washed with PBS and stored as cell pellets at -80°C until RNA extraction. The cell pellets were thawed in 1 mL TRIR (ABgene) at RT for 5 min and total RNA was isolated in 30 μ L using the Aurum Total RNA Mini Kit (Bio-Rad), according to the manufacturer's instructions and including an on-column DNase treatment of 20 min at RT. RNA purity and concentration was measured via Nanodrop analysis (Thermo Scientific) and DNA contamination was checked via minus-RT PCR with the TBP assay. Up to 1 μ g of DNA-free RNA was converted into cDNA with random hexamers and oligo-dT using the ImProm-II Reverse Transcription System (Promega) [63]. The integrity and the PCR amplificability of the cDNA (1/10 dilution) was confirmed via the UBC integrity assay [63].

qPCR reactions were performed on 2 μ L 1/10 diluted cDNA with the KAPA SYBR FAST qPCR Master Mix (KAPA Bio-systems) and 500 nM primers (Table S1) in a final volume of 10 μ L. The reactions were performed on the CFX96 Touch Real-Time PCR Detection System (Bio-Rad). Initial denaturation at 95°C for 3 min to activate the DNA polymerase was followed by 40 cycles of denaturation at 95°C for 20 s and a combined annealing/extension/signal detection step at the primer annealing temperature for 40 s (Table S1). Finally, a melt

TABLE 3 Overview of the panels of the selected primary antibodies to immunophenotype viable bovine MSCs using multicolor flow cytometry.

Antibody	Clone	Isotype	Dilution	Fluorochrome	Manufacturer, product number	Reactivity
Panel 1						
Mo CD29-APC	TS2/16	IgG ₁	1:50		BioLegend, 303,007	Cross-reactive
Mo CD45-FITC	CC1	IgG ₁	1:10		BioRad, MCA832GA	Bovine-specific
Mo MHCII-(R)PE	CC158	IgG _{2a}	1:20		BioRad, MCA5655	Bovine-specific
Ra CD73		IgG	1:50	IgG-APC-Cy7	AAT Bioquest, 16873	Cross-reactive
Ra CD90-biotin		IgG	1:50	Streptavidin PerCP-Cy5.5	Invitrogen, 45-4317-80	Cross-reactive
Panel 2						
Mo CD14-(R)PE	CC-G33	IgG ₁	1:100		BioRad, MCA2678GA	Bovine-specific
Mo CD44-FITC	IL-A118	IgG ₁	1:10		BioRad, MCA2433F	Bovine-specific
Mo CD79 α -AF700	HM57	IgG ₁	1:50			Cross-reactive
Ra CD34		IgG	1:100	IgG-PE-Cy5	ThermoFisher, L43018	Cross-reactive

Note: When appropriate, the relevant secondary labels are also provided.

Abbreviations: (R)PE, R-phycoerythrin; AF700, Alexa Fluor 700; APC, allophycocyanin; APC-Cy7, APC-cyanine 7; FITC, fluorescein isothiocyanate; Ig, immunoglobulin; Mo, mouse; PE-Cy5, PE-Cyanine5; PerCP-Cy5.5, peridinin chlorophyll protein-cyanine5.5; Ra, rabbit.

curve analysis was performed (from 70°C to 95°C with 0.5°C increments of 5 min) to confirm that the detected signals came from the intended amplicons. All reactions were performed in duplicate and a no template control (NTC) was included in each run. A four-fold dilution series of one reference cDNA sample was additionally included for each gene to acquire PCR efficiency based on relative standard curves. Calculation of the C_q-values (quantification cycle), PCR efficiencies, correlation coefficients and analysis of the melting curves was performed by means of the CFX Maestro Software.

After duplicate RT-qPCR experiments, inter-run calibration was performed. When inter-sample variability exceeded a C_q-value of 0.5, a third run was performed. The mean C_q-value of the two or three replicates was used for further data processing. To this end, mean C_q values were transformed, using the exact PCR amplification efficiency, into corrected C_q-values assuming a uniform PCR amplification efficiency of 100% across all samples (Equation 1):

$$C_{q_{\text{corrected}}} = \text{Log}_2 \left(E_{\text{exact}}^{C_{q_{\text{mean}}}} \right). \quad (1)$$

In a preliminary experiment, the expression stability of six commonly used reference genes was determined in the MSC samples [64, 65]. After identifying the most efficient reference genes (ACTB, SDHA, TBP, and HPRT1), NormFinder for Microsoft Excel was applied. Applying this software program, ACTB and TBP were indicated as the most stable genes in MSC samples, since the average stability values of these genes was 0.212. Relative quantification was calculated based on the delta C_q-method, with ACTB and TBP used as reference genes as described [66].

2.7 | Data analysis

Quantitative data are presented as mean ± standard deviation (SD) from seven replicates and visualized using GraphPad Prism 8.

3 | RESULTS

3.1 | Evaluation of cross-reactive antibodies

Using bovine UVECs as appropriate positive controls, cross-reactivity against bovine epitopes was identified for the commercially available Abs directed against CD34 (3.37%), whereas none of the four CD105 Abs and the CD106 Ab tested showed cross-reactivity (Figure 1). Furthermore, cross-reactivity against bovine epitopes was identified for Abs directed against CD73 (17.83%), CD79α (27.41%), and CD90 (16.09%), using bovine LEU as appropriate positive controls (Figure 1). Additionally, binding of the above-mentioned Abs to the bovine positive control cells was confirmed with immunofluorescence microscopy (Figure 1).

3.2 | Tri-lineage differentiation potential of bovine AT-derived MSCs

To confirm the MSC identity of the isolated cells from AT, cells were differentiated toward adipocytes, osteocytes, and chondrocytes, respectively. Tri-lineage differentiation potential was confirmed for all donors (Figure S1).




FIGURE 1 Evaluation of cross-reactive antibodies against mesenchymal stromal cell markers using the appropriate bovine positive control cells. The black histogram represents the negative control, while the green histogram represents the cells stained with the selected antibodies. Immunofluorescence microscopy was used to confirm specific cellular binding. Nuclei were visualized using Hoechst. Scale bar = 10 micron; scale bar inset = 5 micron. EC, endothelial cells; LEU, leukocytes. [Color figure can be viewed at wileyonlinelibrary.com]

3.3 | Immunophenotyping of bovine AT-derived MSCs

Based on the commercially available bovine-specific and the identified cross-reacting Abs, two panels were developed to adequately immunophenotype bovine AT-derived MSCs using multi-color flow cytometry. The gating strategy to assess marker expression of bovine MSCs for panel 1 and 2 is presented in Figure 2. As shown in Figure 3A, bovine AT-derived MSCs uniformly expressed CD29 ($99.95\% \pm 0.04\%$) and CD44 ($93.93\% \pm 4.60\%$), showed a variable expression of CD34 ($76.15\% \pm 19.74\%$) and CD90 ($7.56\% \pm 6.31\%$), and lacked expression of CD14 ($0.30\% \pm 0.19\%$), CD45 ($0.13\% \pm 0.24\%$), CD73 ($0.23\% \pm 0.36\%$), CD79 α ($0.05\% \pm 0.03\%$) and MHCII ($0.18\% \pm 0.13\%$). In panel 1, bovine MSCs are positive for both CD29 and CD90, and negative for CD45, CD73 and MHCII. As all cells are expressing CD29, the same variation in percentage CD90⁺ cells is observed when focusing either on the total cell population or only on the CD29⁺ cells. In panel 2, bovine MSCs are positive for CD34 and CD44, and negative for CD14 and CD79 α . Most cells in panel 2 co-express both CD34 and CD44 (76.78 ± 18.26), while some cells lack expression of both markers (2.90 ± 2.64) or express only CD34 (4.46 ± 2.69) or only CD44 (15.85 ± 16.87) (Figure 3B).

To evaluate marker expression on transcript level, mRNA expression of MSC markers was assessed by RT-qPCR. RNA yield concentrations ranged between 70 and 121 ng/ μ L and RNA samples gave a 260/280 ratio between 1.9 and 2.1. Bovine AT-MSCs showed a higher mRNA expression of CD29, CD44 and CD90 ($-\Delta\text{Cq} > 0$), a moderate expression of CD34 and CD105 ($-5 \leq -\Delta\text{Cq} \leq 0$), and a low expression of CD14, CD73, CD79 α and MHCII ($-\Delta\text{Cq} < -5$), when compared to the reference genes (Figure 4). CD45 was not expressed above the detection limit of the RT-qPCR assay (Figure 4).

4 | DISCUSSION

In general, the immunophenotypic characterization of bovine MSCs is hampered by the lack of bovine-specific or validated cross-reactive mAbs. In this study, 13 commercially available Abs were screened to compose two panels of bovine-specific and/or cross-reactive Abs. Cross-reactivity with bovine epitopes was identified for Abs directed against CD34, CD73, CD79 α and CD90. Unfortunately, no cross-reactive Abs were identified against CD105 and CD106. Although the Abs directed against CD29 (TS2/16) and CD79 α (HM57) were already used to identify bovine cells [67–70], they were not validated yet using the appropriate positive control cells. This validation is important as it turned out that three of the four tested anti-CD105 clones (SN6, SN6h, and 2Q1707) were already used to characterize bovine MSCs [40, 46, 67], while, in our hands, these antibodies did not bind to both bovine adipose tissue-derived MSCs and UVECs. The tissue of origin of the MSCs might explain the difference in CD105 expression by MSCs reported in these studies and in our study [40, 46, 71]. On the other hand, the polyclonal CD34 Ab was evaluated in this study, although only a low percentage of positive cells was observed

in the positive control, most likely because the primary endothelial cells were not purified. This is in line with other reports where human and bovine primary endothelial cells were reported to show variable CD34 expression [72, 73].

Based on the evaluated cross-reactive and bovine-specific Abs, two panels were developed to adequately immunophenotype bovine MSCs. The use of multi-color flow cytometry enhances the characterization of the heterogenous MSC population [74]. Similar to human MSCs, bovine MSCs highly expressed CD29 and CD44, and lacked expression of CD14, CD45, CD79 α , and MHCII. However, some remarkable differences in marker expression between human and bovine MSCs were observed. Bovine AT-derived MSCs showed a variable expression of the hematopoietic stem and progenitor marker CD34, only a low expression of CD90, and lacked expression of CD73. These results were largely similar on the mRNA level.

As already mentioned, a variable CD34 expression is described for both human and bovine MSCs, depending on sources and passages [13, 40, 54, 75, 76]. It is hypothesized that MSCs originate from the perivascular cell population as they share markers and functionality with perivascular and mural cells [12, 77]. This might explain the CD34 positivity of certain MSC subpopulations. Traktuev et al. (2008), for example, identified a subpopulation of human AT-derived stem cells that is, CD34⁺/CD31⁻/CD144⁻ cells, which simultaneously expressed mesenchymal, pericytic and smooth muscle markers [77]. For bovine MSCs, mostly CD34 negativity is reported at the mRNA and protein level (Table 1). As proper Ab evaluation and/or quantitative data on CD34 expression, in case of immunofluorescent staining of bovine MSCs, is often lacking [16, 19, 27, 47, 49, 50], defining bovine MSCs as CD34 negative cells remains a point of discussion [12]. Furthermore, CD34 positivity has been reported for bovine MSCs isolated from placental tissues [40, 54].

Interestingly, CD73, known to be expressed by human MSCs, was negative in the bovine AT-derived MSC population, as confirmed on both the mRNA and protein level. In general, CD73 positivity has been reported for bovine MSCs (Table 1). In parallel with CD34 expression, proper Ab evaluation and quantitative data at the protein level is often lacking [15, 26, 41]. In one bovine study, however, lung-derived MSCs showed low CD73 mRNA levels in passage 3 and 9, with an increased expression observed in passage 17 and 25 [26]. Low CD73 expression was also observed for equine MSCs isolated from umbilical cord blood, Whartons Jelly and peripheral blood [78]. Recently, two subpopulations based on the presence or absence of CD73 expression were identified in murine MSCs, isolated from pericardial AT [79]. Additionally, these researchers observed a heterogenous CD73 expression (ranging from 19% to 84%) in MSCs from other murine sources as well, such as bone marrow, subcutaneous AT and umbilical cord [79].

Regarding CD90 expression, a discrepancy between mRNA and protein level was observed in this study, with a high mRNA level but a rather low expression on the protein level. This finding confirms that the absence of the corresponding proteins is preferably evaluated rather than their mRNA levels [80]. Low expression of CD90 was reported as well in two other bovine MSC studies. In the study of





FIGURE 2 Gating strategy for bovine mesenchymal stromal cells, (A) for panel 1 and (B) panel 2. First, singlets were selected in FSC-A/FSC-H (P1) and SSC-A/SSC-H (P2) dot plots. The population of interest (P) was identified based on side scatter area versus forward scatter area (SSC-A/FSC-A) characteristics. The viable single cell population (P4) was then identified by Sytox Blue (panel 1) or fixable violet blue (panel 2) staining. The final gate for analysis (P5) was identified by defining unspecific binding to cells in P4 using fluorescence minus one (FMO) controls. Marker expression of a representative donor for panel 1 and panel 2 is shown. [Color figure can be viewed at wileyonlinelibrary.com]

Pipino et al. (2018), only a fraction (30%–40%) of bovine MSCs isolated from milk was CD90⁺ [46], while Xiong et al. observed low mRNA expression of CD90 in MSC from bovine umbilical cord [31].

In conclusion, a multi-color flow cytometry protocol was developed to immunophenotype bovine MSCs after properly evaluating cross-reacting Abs. In a recent ISCT communication, it is stated that

FIGURE 3 Immunophenotypic profile of bovine AT-mesenchymal stromal cells (MSCs) as assessed by multi-color flow cytometry. The expression of nine MSC markers was evaluated on bovine AT-derived MSCs ($n = 7$). (A) The horizontal line shows the mean % positive cells and the error bars the standard deviation. The dotted line shows the 2% positive cells, i.e. the upper limit set by the ISCT to determine ‘lack of expression’ ($\leq 2\%$). (B) Representative image of co-expression of CD44 and CD34, i.e. the only positive markers in panel 2.



the characterization of MSCs, as defined by cell surface marker expression, is evolving as new insights are gained [12]. It is also clear that several subpopulations are present within the MSC population [79]. Such heterogeneity may also reflect differences in proliferation and differentiation potential. Suga et al. (2009), for example, showed that human AT-derived CD34⁺ MSCs exhibited a higher proliferative potential, while CD34⁻ MSCs showed a greater ability for adipogenic and osteogenic differentiation [14]. When considering bovine MSCs as alternative cell source to produce cultured meat, it is important to identify those MSC subpopulations which are able to proliferate on the one hand (in order to generate large

amounts of cultured meat) and to differentiate myogenically on the other hand. The immunophenotypic characterization protocol described in this study provides an interesting tool to rapidly identify different MSC subpopulations. In future research, the proliferation and myogenic differentiation potential of the different MSC subpopulations should be evaluated after sorting, to identify the most appropriate MSC subpopulation to produce cultured meat. Furthermore, our results suggest that species-specific immunophenotypic profiles should be formulated when characterizing MSCs, as it is clear from this study and other studies that the expression of the commonly used panel of MSC markers is highly variable and




FIGURE 4 mRNA expression profile of bovine AT-MSCs as assessed by RT-qPCR. Relative expression ($-\Delta Cq$) compared to reference genes of the markers for bovine AT-derived-MSCs ($n = 7$). High mRNA expression indicated as $-\Delta Cq > 0$, moderate mRNA expression indicated as $-5 \leq -\Delta Cq \leq 0$, low mRNA expression indicated as $-\Delta Cq < -5$ when compared to reference genes (A); Heatmap representing the relative expression. Dark green shades indicate higher expression and dark blue shades indicate lower expression; white shades indicate $-\Delta Cq$ values = 0; gray shades indicate missing values, marker gene expression was not expressed above the detection limit of the RT-qPCR assay (B). [Color figure can be viewed at wileyonlinelibrary.com]

depends on the species, tissue of origin, donors, passages, and culture conditions.

AUTHOR CONTRIBUTIONS

Emma Heyman was involved in conception and design, execution of experiments and manuscript writing. M. Meeremans was involved in RT-qPCR experiments and data analysis. M. Van Poucke and L. Peelman were involved in RT-qPCR experiments and manuscript writing. Catharina De Schauwer and B. Devriendt were involved in conception and design, data analysis and manuscript writing.

ACKNOWLEDGMENTS

We gratefully acknowledge Joachim Christiaens and Delphine Ameye (Department of Pathobiology, Pharmacology and Zoological Medicine, Faculty of Veterinary Medicine, Ghent University) for their excellent technical assistance.

FUNDING INFORMATION

This study was partially funded by the CUSTOMEAT project (FWO-SBO project S002821N).

CONFLICT OF INTEREST STATEMENT

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

DATA AVAILABILITY STATEMENT

An example of the multi-color flow cytometry results (FCS-files) was uploaded to the Flow Repository website: <http://flowrepository.org/id/FR-FCM-Z64A>. Additional data files presented in this study are available upon request, please contact the corresponding author Emma Heyman.

REFERENCES

- Munteanu C, Mireșan V, Răducu C, Ihuț A, Uiuu P, Pop D, et al. Can cultured meat be an alternative to farm animal production for a sustainable and healthier lifestyle? *Front Nutr*. 2021;8:749298.
- Stephens N, di Silvio L, Dunsford I, Ellis M, Glencross A, Sexton A. Bringing cultured meat to market: technical, socio-political, and regulatory challenges in cellular agriculture. *Trends Food Sci Technol*. 2018;78:155–66.
- Tuomisto HL, Teixeira De Mattos MJ. Environmental impacts of cultured meat production. *Environ Sci Technol*. 2011;45:6117–23.
- Judson RN, Rossi FMV. Towards stem cell therapies for skeletal muscle repair. *npj Regen Med*. 2020;5:10.
- Ben-Arye T, Levenberg S. Tissue engineering for clean meat production. *Front Sustain Food Syst*. 2019;3:46.
- Du M, Yin J, Zhu MJ. Cellular signaling pathways regulating the initial stage of adipogenesis and marbling of skeletal muscle. *Meat Sci*. 2010;86:103–9.
- Okamura LH, Cordero P, Palomino J, Parraguez VH, Torres CG, Peralta OA. Myogenic differentiation potential of mesenchymal stem cells derived from fetal bovine bone marrow. *Anim Biotechnol*. 2018; 29:1–11.
- Jana S, Levengood SKL, Zhang M. Anisotropic materials for skeletal-muscle-tissue engineering. *Adv Mater*. 2016;28:10588–612.
- Hill ABT, Bressan FF, Murphy BD, Garcia JM. Applications of mesenchymal stem cell technology in bovine species. *Stem Cell Res Ther*. 2019;10:44.
- Gugjoo MB, Amarpal FMR, Shah RA, Sharma GT. Mesenchymal stem cell: basic research and potential applications in cattle and buffalo. *J Cell Physiol*. 2019;234:8618–35.
- Dominici M, le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*. 2006;8:315–7.
- Viswanathan S, Shi Y, Galipeau J, Krampera M, Leblanc K, Martin I, et al. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT[®]) mesenchymal stromal cell committee position statement on nomenclature. *Cytotherapy*. 2019;21: 1019–24.
- Lin CS, Ning H, Lin G, Lue TF. Is CD34 truly a negative marker for mesenchymal stromal cells? *Cytotherapy*. 2012;14:1159–63.
- Suga H, Matsumoto D, Eto H, Inoue K, Aoi N, Kato H, et al. Functional implications of CD34 expression in human adipose-derived stem/progenitor cells. *Stem Cells Dev*. 2009;18:1201–9.

15. Lee J, Byeon JS, Gu NY, Lee S, Lee SA, Jeong DU, et al. Bovine tongue epithelium-derived cells: a new source of bovine mesenchymal stem cells. *Biosci Rep.* 2020;40:1–12.
16. Yue Y, Zhang L, Zhang X, Li X, Yu H. De novo lipogenesis and desaturation of fatty acids during adipogenesis in bovine adipose-derived mesenchymal stem cells. *In Vitro Cell Dev Biol Anim.* 2018;54:23–31.
17. Da Silva CG, Martins CF, Cardoso TC, da Cunha ER, Bessler HC, Martins GHL, et al. Production of bovine embryos and calves cloned by nuclear transfer using mesenchymal stem cells from amniotic fluid and adipose tissue. *Cell Reprogram.* 2016;18:127–36.
18. Corradetti B, Meucci A, Bizzaro D, Cremonesi F, Lange CA. Mesenchymal stem cells from amnion and amniotic fluid in the bovine. *Reproduction.* 2013;145:391–400.
19. Gao Y, Zhu Z, Zhao Y, Hua J, Ma Y, Guan W. Multilineage potential research of bovine amniotic fluid mesenchymal stem cells. *Int J Mol Sci.* 2014;15:3698–710.
20. Chang LB, Peng SY, Chou CJ, Chen YJ, Shiu JS, Tu PA, et al. Therapeutic potential of amniotic fluid stem cells to treat bilateral ovarian dystrophy in dairy cows in a subtropical region. *Reprod Domest Anim.* 2017;1-9:433–41.
21. Lu T, Huang Y, Wang H, Ma Y, Guan W. Multi-lineage potential research of bone marrow-derived stromal cells (BMSCs) from cattle. *Appl Biochem Biotechnol.* 2014;172:21–35.
22. Lee SH, Cha SH, Kim CL, Lillehoj HS, Song JY, Lee KW. Enhanced adipogenic differentiation of bovine bone marrow-derived mesenchymal stem cells. *J Appl Anim Res.* 2015;43:15–21.
23. Ramírez-Espinosa JJ, González-Dávalos L, Shimada A, Pinã E, Varela-Echavarría A, Mora O. Bovine (*Bos taurus*) bone marrow mesenchymal cell differentiation to Adipogenic and myogenic lineages. *Cells Tissues Organs.* 2015;201:51–64.
24. Lu T, Hu P, Su X, Li C, Ma Y, Guan W. Isolation and characterization of mesenchymal stem cells derived from fetal bovine liver. *Cell Tissue Bank.* 2014;15:439–50.
25. Gao Y, Wu Y, Wen H, Zhu W, Ren H, Guan W, et al. Multilineage potential research on pancreatic mesenchymal stem cells of bovine. *Tissue Cell.* 2019;56:60–70.
26. Hu P, Pu Y, Li X, Zhu Z, Zhao Y, Guan W, et al. Isolation, in vitro culture and identification of a new type of mesenchymal stem cell derived from fetal bovine lung tissues. *Mol Med Rep.* 2015;12:3331–8.
27. Lu T, Xiong H, Wang K, Wang S, Ma Y, Guan W. Isolation and characterization of adipose-derived mesenchymal stem cells (ADSCs) from cattle. *Appl Biochem Biotechnol.* 2014;174:719–28.
28. Da Silva CG, Martins CF, Cardoso TC, da Cunha ER, Bessler HC, McManus CM, et al. Isolation and characterization of mesenchymal stem cells derived from bovine Wharton's jelly and their potential for use in cloning by nuclear transfer. *Cienc Rural.* 2016;46:1830–7.
29. Lange-Consiglio A, Perrini C, Bertero A, Esposti P, Cremonesi F, Vincenti L. Isolation, molecular characterization, and in vitro differentiation of bovine Wharton jelly-derived multipotent mesenchymal cells. *Theriogenology.* 2017;89:338–47.
30. Sun T, Yu C, Gao Y, Zhao C, Hua J, Cai L, et al. Establishment and biological characterization of a dermal mesenchymal stem cells line from bovine. *Biosci Rep.* 2014;34:139–46.
31. Xiong H, Bai C, Wu S, Gao Y, Lu T, Hu Q, et al. Biological characterization of mesenchymal stem cells from bovine umbilical cord. *Anim Cells Syst.* 2014;18:59–67.
32. Cardoso TC, Okamura LH, Baptistella JC, Gameiro R, Ferreira HL, Marinho M, et al. Isolation, characterization and immunomodulatory-associated gene transcription of Wharton's jelly-derived multipotent mesenchymal stromal cells at different trimesters of cow pregnancy. *Cell Tissue Res.* 2017;367:243–56.
33. Dueñas F, Becerra V, Cortes Y, Vidal S, Sáenz L, Palomino J, et al. Hepatogenic and neurogenic differentiation of bone marrow mesenchymal stem cells from abattoir-derived bovine fetuses. *BMC Vet Res.* 2014;10:154.
34. De Moraes CN, Maia L, de Oliveira E, de Paula Freitas Dell'Aqua C, Chapwanya A, da Cruz Landim-Alvarenga F, et al. Shotgun proteomic analysis of the secretome of bovine endometrial mesenchymal progenitor/stem cells challenged or not with bacterial lipopolysaccharide. *Vet Immunol Immunopathol.* 2017;187:42–7.
35. Cardoso TC, Ferrari HF, Garcia AF, Novais JB, Silva-Frade C, Ferrarezi MC, et al. Isolation and characterization of Wharton's jelly-derived multipotent mesenchymal stromal cells obtained from bovine umbilical cord and maintained in a defined serum-free three-dimensional system. *BMC Biotechnol.* 2012;12:18.
36. Lara E, Velásquez A, Cabezas J, Rivera N, Pacha P, Rodríguez-Alvarez L, et al. Endometritis and in vitro PGE2 challenge modify properties of cattle endometrial mesenchymal stem cells and their transcriptomic profile. *Stem Cells Int.* 2017;2017:1–16.
37. Lara E, Rivera N, Rojas D, Rodríguez-Alvarez LL, Castro FO. Characterization of mesenchymal stem cells in bovine endometrium during follicular phase of oestrous cycle. *Reprod Domest Anim.* 2017;52:707–14.
38. Campos LL, Landim-Alvarenga FC, Ikeda TL, Monteiro BA, Maia L, Freitas-Dell'Aqua CP, et al. Isolation, culture, characterization and cryopreservation of stem cells derived from amniotic mesenchymal layer and umbilical cord tissue of bovine fetuses. *Pesqui Vet Bras.* 2017;37:278–86.
39. Calle A, López-Martín S, Monguió-Tortajada M, Borràs FE, Yáñez-Mó M, Ramírez MÁ. Bovine endometrial MSC: mesenchymal to epithelial transition during luteolysis and tropism to implantation niche for immunomodulation. *Stem Cell Res Ther.* 2019;10:23.
40. Mançanares CAF, Oliveira VC, Oliveira LJ, Carvalho AF, Sampaio RV, Mançanares ACF, et al. Isolation and characterization of mesenchymal stem cells from the yolk sacs of bovine embryos. *Theriogenology.* 2015;84:887–98.
41. Oyarzo R, Valderrama X, Valenzuela F, Bahamonde J. Bovine fetal mesenchymal stem cells obtained from omental adipose tissue and placenta are more resistant to cryoprotectant exposure than those from bone marrow. *Front Vet Sci.* 2021;8:708972.
42. Nawaz S, Özden Akkaya Ö, Dikmen T, Altunbaş K, Yağci A, Kibria ASMG, et al. Molecular characterization of bovine amniotic fluid derived stem cells with an underlying focus on their comparative neuronal potential at different passages. *Ann Anat.* 2020;228:151452.
43. Cortes Y, Ojeda M, Araya D, Dueñas F, Fernández MS, Peralta OA. Isolation and multilineage differentiation of bone marrow mesenchymal stem cells from abattoir-derived bovine fetuses. *BMC Vet Res.* 2013;9:133.
44. Raoufi MF, Tajik P, Dehghan MM, Eini F, Barin A. Isolation and differentiation of mesenchymal stem cells from bovine umbilical cord blood. *Reprod Domest Anim.* 2011;46:95–9.
45. Debbarma P, Mondal T, Manna C, Kumar K, Mukherjee J, Das BC, et al. Post-calving umbilical cord tissue offcut: a potential source for the isolation of bovine mesenchymal stem cells. *Vet World.* 2020;13:2772–9.
46. Pipino C, Mandatori D, Buccella F, Lanuti P, Preziuso A, Castellani F, et al. Identification and characterization of a stem cell-like population in bovine milk: a potential new source for regenerative medicine in veterinary. *Stem Cells Dev.* 2018;27:1587–97.
47. Miranda MS, Nascimento HS, Costa MPR, Costa NN, Brito KNL, Lopes CTA, et al. Increasing of blastocyst rate and gene expression in co-culture of bovine embryos with adult adipose tissue-derived mesenchymal stem cells. *J Assist Reprod Genet.* 2016;33:1395–403.
48. Cebo D. Characterization of bovine adipose-derived stem cells. *Int J Sci Technol Res.* 2017;6:16–8.
49. Hanga MP, Ali J, Moutsatsou P, de la Raga FA, Hewitt CJ, Nienow A, et al. Bioprocess development for scalable production of cultivated meat. *Biotechnol Bioeng.* 2020;117:3029–39.
50. Sampaio R, Chiaratti MR, Santos DCN, Bressan FF, Sangalli JR, Sá ALA, et al. Generation of bovine (*Bos indicus*) and buffalo (*Bubalus*

- bubalis*) adipose tissue derived stem cells: isolation, characterization, and multipotentiality. *Genet Mol Res.* 2015;14:53–62.
51. Zhang Q, Xu Y, Xu J. Targeting heterogeneity of mesenchymal stem cells. *Front Cell Dev Biol.* 2022;10:894008.
 52. Merlo B, Gugole PM, Iacono E. An update on applications of cattle mesenchymal stromal cells. *Animals.* 2022;12:1956.
 53. Kato Y, Imabayashi H, Mori T, Tani T, Taniguchi M, Higashi M, et al. Nuclear transfer of adult bone marrow mesenchymal stem cells: developmental totipotency of tissue-specific stem cells from an adult mammal. *Biol Reprod.* 2004;70:415–8.
 54. Rossi B, Merlo B, Colleoni S, Iacono E, Tazzari PL, Ricci F, et al. Isolation and in vitro characterization of bovine amniotic fluid derived stem cells at different trimesters of pregnancy. *Stem Cell Rev Rep.* 2014;10:712–24.
 55. Wruck W, Graffmann N, Spitzhorn LS, Adjaye J. Human induced pluripotent stem cell-derived mesenchymal stem cells acquire rejuvenation and reduced heterogeneity. *Front Cell Dev Biol.* 2021;9:717772.
 56. Baumgarth N, Roederer M. A practical approach to multicolor flow cytometry for immunophenotyping. *J Immunol.* 2000;243:77–97.
 57. Baer PC, Kuçi S, Krause M, Kuçi Z, Zielen S, Geiger H, et al. Comprehensive phenotypic characterization of human adipose-derived stromal/stem cells and their subsets by a high throughput technology. *Stem Cells Dev.* 2012;22:330–9.
 58. Naraoka Y, Mabuchi Y, Yoneyama Y, Suto EG, Hisamatsu D, Ikeda M, et al. Isolation and characterization of tissue resident cd29-positive progenitor cells in livestock to generate a three-dimensional meat bud. *Cell.* 2021;10:2499.
 59. De Schauwer C, Piepers S, Hoogewijs MK, Govaere JLJ, Rijsselaere T, Demeyere K, et al. Optimization of the isolation, culture, and characterization of equine umbilical cord blood mesenchymal stromal cells. *Tissue Eng: Part C.* 2011;17:1061–70.
 60. Olyslaegers DAJ, Desmarests LMB, Dedeurwaerder A, Dewerchin HL, Nauwynck HJ. Generation and characterization of feline arterial and venous endothelial cell lines for the study of the vascular endothelium. *BMC Vet Res.* 2013;9:170.
 61. Heyman E, Meeremans M, Devriendt B, Olenic M, Chiers K, de Schauwer C. Validation of a color deconvolution method to quantify MSC tri-lineage differentiation across species. *Front Vet Sci.* 2022;9:987045.
 62. De Schauwer C, Piepers S, van de Walle GR, Demeyere K, Hoogewijs MK, Govaere JLJ, et al. In search for cross-reactivity to immunophenotype equine mesenchymal stromal cells by multicolor flow cytometry. *Cytometry.* 2012;81A:312–23.
 63. Van Poucke M, Peelman LJ. Flexible, multi-use, PCR-based nucleic acid integrity assays based on the ubiquitin C gene. *BioRxiv* 168195 2017.
 64. Verbeke J, van Poucke M, Peelman L, de Vlieghe S. Differential expression of CXCR1 and commonly used reference genes in bovine milk somatic cells following experimental intramammary challenge. *BMC Genet.* 2015;16:40.
 65. Goossens K, van Poucke M, van Soom A, Vandesompele J, van Zeveren A, Peelman LJ. Selection of reference genes for quantitative real-time PCR in bovine preimplantation embryos. *BMC Dev Biol.* 2005;5:27.
 66. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. *Nat Protoc.* 2008;3:1101–8.
 67. Ding S, Swennen GNM, Messmer T, Gagliardi M, Molin DGM, Li C, et al. Maintaining bovine satellite cells stemness through p38 pathway. *Sci Rep.* 2018;8:10808.
 68. Cantón GJ, Katzer F, BenavidesSilván J, Maley SW, Palarea Albaladejo J, Pang Y, et al. Phenotypic characterisation of the cellular immune infiltrate in placentas of cattle following experimental inoculation with *Neospora caninum* in late gestation. *Vet Res.* 2013;44:60.
 69. Maley SW, Buxton D, Macaldowie CN, Anderson IE, Wright SE, Bartley PM, et al. Characterization of the immune response in the placenta of cattle experimentally infected with *Neospora caninum* in early gestation. *J Comp Pathol.* 2006;135:130–41.
 70. Ekman A, Pessa-Morikawa T, Liljavirta J, Nika M, Iivanainen A. B-cell development in bovine fetuses proceeds via a pre-B like cell in bone marrow and lymph nodes. *Dev Comp Immunol.* 2010;34:896–903.
 71. Sandhu MA, Jurek S, Trappe S, Kolisek M, Sponder G, Aschenbach JR. Influence of bovine serum lipids and fetal bovine serum on the expression of cell surface markers in cultured bovine preadipocytes. *Cells Tissues Organs.* 2017;204:13–24.
 72. Mou Y, Yue Z, Zhang H, Shi X, Zhang M, Chang X, et al. High quality in vitro expansion of human endothelial progenitor cells of human umbilical vein origin. *Int J Med Sci.* 2017;14:294–301.
 73. Jiménez-Meléndez A, Fernández-Álvarez M, Calle A, Ramírez MÁ, Diezma-Díaz C, Vázquez-Arbaizar P, et al. Lytic cycle of *Besnoitia besnoiti* tachyzoites displays similar features in primary bovine endothelial cells and fibroblasts. *Parasit Vectors.* 2019;12:517.
 74. Baer PC, Geiger H. Adipose-derived mesenchymal stromal/stem cells: tissue localization, characterization, and heterogeneity. *Stem Cells Int.* 2012;1–10.
 75. Mitchell JB, McIntosh K, Zvonik S, Garrett S, Floyd ZE, Kloster A, et al. Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem cell-associated markers. *Stem Cells.* 2006;24:376–85.
 76. Elahi KC, Klein G, Avci-Adali M, Sievert KD, Macneil S, Aicher WK. Human mesenchymal stromal cells from different sources diverge in their expression of cell surface proteins and display distinct differentiation patterns. *Stem Cells Int.* 2016;2016:1–9.
 77. Traktuev DO, Merfeld-Clauss S, Li J, Kolonin M, Arap W, Pasqualini R, et al. A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. *Circ Res.* 2008;102:77–85.
 78. De Schauwer C, Goossens K, Piepers S, Hoogewijs MK, Govaere JL, Smits K, et al. Characterization and profiling of immunomodulatory genes of equine mesenchymal stromal cells from non-invasive sources. *Stem Cell Res Ther.* 2014;5:6.
 79. Tan K, Zhu H, Zhang J, Ouyang W, Tang J, Zhang Y, et al. CD73 expression on mesenchymal stem cells dictates the reparative properties via its anti-inflammatory activity. *Stem Cells Int.* 2019;2019:1–12.
 80. De Sousa AR, Penalva LO, Marcotte EM, Vogel C. Global signatures of protein and mRNA expression levels. *Mol Biosyst.* 2009;5:1512–26.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Heyman E, Meeremans M, Van Poucke M, Peelman L, Devriendt B, De Schauwer C. Validation of multiparametric panels for bovine mesenchymal stromal cell phenotyping. *Cytometry.* 2023. <https://doi.org/10.1002/cyto.a.24737>